Form 4: Day One Biopharmaceuticals Director Acquires Stock Options

Garry A. Nicholson, a director of Day One Biopharmaceuticals, acquired stock options for 32,335 shares of common stock on May 23, 2024.

Summary

• Garry A. Nicholson, a director of Day One Biopharmaceuticals, filed a Form 4 to report changes in beneficial ownership.
• On May 23, 2024, Nicholson acquired stock options for 32,335 shares of Day One Biopharmaceuticals' common stock at an exercise price of $13.87.
• The options vest monthly, starting June 23, 2024, contingent upon Nicholson's continued service to the company.
• The options expire on May 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director, which is a routine event. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (32,335 shares) would need to be compared to grants made to directors at comparable companies to determine if it is within industry norms.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates